SCHEMBL7121175

SCHEMBL7121175

CCN(CC)CCCNC1(c2ccccc2)Oc2ccccc2N(C)C1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
ALOX15 P16050 2/20 0.37
NISCH Q9Y2I1 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PIM1 P11309 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GAA P10253 1/20 0.35
SIGMAR1 Q99720 2/20 0.35
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
ADK P55263 1/20 0.35
APAF1 O14727 1/20 0.34
NPC1 O15118 1/20 0.34
MITF O75030 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7114679 0.75 BCHE (0.41) ALDH1A1MEN1KMT2AGAAAPAF1
SCHEMBL11713969 0.63 FAAH (0.57) MEN1KMT2ASIGMAR1HRH1
SCHEMBL29209006 0.63 NISCH (0.47) ALDH1A1NISCHMEN1KMT2ATDP1
SCHEMBL16362032 0.62 NISCH (0.52) ALDH1A1NISCHMEN1KMT2ANPC1
SCHEMBL9419633 0.61 PIM1 (0.71) ALDH1A1ALOX15MEN1KMT2APIM1
SCHEMBL8630509 0.60 NISCH (0.47) ALDH1A1NISCHNPC1MAPTRAB9A
SCHEMBL8630646 0.60 NISCH (0.47) ALDH1A1NISCHNPC1MAPTRAB9A
SCHEMBL9419622 0.60 PIM1 (0.78) ALDH1A1ALOX15MEN1KMT2APIM1
SCHEMBL8627514 0.60 NISCH (0.47) ALDH1A1NISCHNPC1MAPTRAB9A
SCHEMBL6164283 0.58 MAOA (0.60) MEN1KMT2ATDP1GAASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030187256-A1 Benoxazinones/benzothiazinones as serine protease inhibitors BERRYMAN KENT ALAN (US) 2003-10-02 US claimed
US-6509335-B1 This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of WARNER-LAMBERT COMPANY 2003-01-21 US claimed
US-20030187256-A1 Benoxazinones/benzothiazinones as serine protease inhibitors BERRYMAN KENT ALAN (US) 2003-10-02 US disclosed
US-6509335-B1 This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of WARNER-LAMBERT COMPANY 2003-01-21 US disclosed
EP-1068191-A1 BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2001-01-17 EP disclosed
WO-1999050257-A1 BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1999-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187256-A1 Benoxazinones/benzothiazinones as serine protease inhibitors HABP2, SPINT2, SERPINB1 ALDH1A1 2444/4885ALOX15 594/4885NISCH 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.